Alternative Data for Assertio Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 2 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 2,000 | Sign up | Sign up | Sign up |
| Employee Rating | 70 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 11 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 15,787 | Sign up | Sign up | Sign up |
| X Followers | 61 | Sign up | Sign up | Sign up |
| X Mentions | 1 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 32 | Sign up | Sign up | Sign up |
| Linkedin Employees | 65 | Sign up | Sign up | Sign up |
About Assertio Therapeutics
Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system.
| Price | $11.64 |
| Target Price | Sign up |
| Volume | 27,590 |
| Market Cap | $74M |
| Year Range | $9.07 - $14.62 |
| Dividend Yield | 0% |
| Analyst Rating | 80% buy |
| Industry | Biotechnology |
In the news
 |
Assertio Announces Publication of Rolvedon® Same-Day Dosing Clinical TrialJanuary 9 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 49M | 14M | 36M | 11M | 18M | 0.180 |
| Q2 '25 | 29M | 11M | 19M | -16M | -6.4M | 0.020 |
| Q1 '25 | 26M | 7.8M | 19M | -14M | -3.4M | -0.040 |
| Q4 '24 | 32M | 12M | 21M | -10M | -2.1M | -0.030 |
| Q3 '24 | 29M | 7.6M | 22M | -2.9M | 4.6M | -0.030 |
Insider Transactions View All
| Stark David Matthew filed to sell 98,541 shares at $0.8. November 12 '25 |
| Mason Heather L filed to buy 287,650 shares at $0.8. November 19 '24 |
| O'Grady Brendan P. filed to buy 11,706 shares at $0.9. November 15 '24 |
| Vacirca Jeff L filed to buy 151,159 shares at $1.1. June 12 '24 |
| Mason Heather L filed to buy 212,650 shares at $1. June 6 '24 |
Similar companies
Read more about Assertio Therapeutics (ASRT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Assertio Therapeutics
The Market Cap of Assertio Therapeutics is $74M.
Currently, the price of one share of Assertio Therapeutics stock is $11.64.
The ASRT stock price chart above provides a comprehensive visual representation of Assertio Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Assertio Therapeutics shares. Our platform offers an up-to-date ASRT stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Assertio Therapeutics (ASRT) does not offer dividends to its shareholders. Investors interested in Assertio Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Assertio Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
